Shield plans £110m London IPO to fund Ferinject challenger
This article was originally published in Scrip
Executive Summary
Shield Therapeutics, which is awaiting European marketing review for its novel oral iron replacement drug Feraccru (ST10, ferric maltol), plans to raise up to £110m an initial public offering (IPO) on the London Stock Exchange. The money will fund the company "through to self-sufficiency," CEO Carl Strerrit told Scrip.